Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER trial
NA Marston, FK Kamanu, F Nordio, Y Gurmu… - Circulation, 2020 - Am Heart Assoc
Background: The ability of a genetic risk score to predict risk in established cardiovascular
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score Results From the FOURIER Trial
NA Marston, FK Kamanu, F Nordio, Y Gurmu, C Roselli… - Circulation, 2020 - research.rug.nl
Background: The ability of a genetic risk score to predict risk in established cardiovascular
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score
NA Marston, FK Kamanu, F Nordio, Y Gurmu, C Roselli… - Circulation, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> The ability of a genetic risk
score to predict risk in established cardiovascular disease and identify individuals who …
score to predict risk in established cardiovascular disease and identify individuals who …
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score
NA Marston, FK Kamanu, F Nordio, Y Gurmu… - Circulation, 2020 - Am Heart Assoc
BACKGROUND: The ability of a genetic risk score to predict risk in established
cardiovascular disease and identify individuals who derive greater benefit from PCSK9 …
cardiovascular disease and identify individuals who derive greater benefit from PCSK9 …
[PDF][PDF] Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score
NA Marston, FK Kamanu, F Nordio, Y Gurmu… - Circulation, 2020 - researchgate.net
BACKGROUND: The ability of a genetic risk score to predict risk in established
cardiovascular disease and identify individuals who derive greater benefit from PCSK9 …
cardiovascular disease and identify individuals who derive greater benefit from PCSK9 …
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.
NA Marston, FK Kamanu, F Nordio, Y Gurmu, C Roselli… - Circulation, 2019 - europepmc.org
Background The ability of a genetic risk score to predict risk in established cardiovascular
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
[PDF][PDF] Predicting Benefit from Evolocumab Therapy in Patients with Atherosclerotic Disease Using a Genetic Risk Score: Results from the FOURIER Trial
NA Marston, FKK MD - timi.org
Predicting Benefit from Evolocumab Therapy in Patients with Atherosclerotic Disease Using a
Genetic Risk Score: Results from the Page 1 ScientificSessions.org #AHA19 Predicting Benefit …
Genetic Risk Score: Results from the Page 1 ScientificSessions.org #AHA19 Predicting Benefit …
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial
NA Marston, FK Kamanu, F Nordio, Y Gurmu, C Roselli… - 2020 - pubmed.ncbi.nlm.nih.gov
Background The ability of a genetic risk score to predict risk in established cardiovascular
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
[HTML][HTML] Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial
NA Marston, FK Kamanu, F Nordio, Y Gurmu… - Circulation, 2020 - ncbi.nlm.nih.gov
BACKGROUND: The ability of a genetic risk score to predict risk in established
cardiovascular disease and identify individuals who derive greater benefit from PCSK9 …
cardiovascular disease and identify individuals who derive greater benefit from PCSK9 …
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial
NA Marston, FK Kamanu, F Nordio, Y Gurmu… - …, 2020 - ingentaconnect.com
Background: The ability of a genetic risk score to predict risk in established cardiovascular
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …
disease and identify individuals who derive greater benefit from PCSK9 (proprotein …